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Abstract: To the best of our knowledge, a dose-response meta-analysis of the relationship between 
cardiovascular disease (CVD) and arsenic (As) exposure at drinking water As concentrations lower 
than the WHO provisional guideline value (10 µg/L) has not been published yet. We conducted a 
systematic review and meta-analyses to estimate the pooled association between the relative risk of 
each CVD endpoint and low-level As concentration in drinking water both linearly and non-linearly 
using a random effects dose-response model. In this study, a significant positive association was 
found between the risks of most CVD outcomes and drinking water As concentration for both linear 
and non-linear models (p-value for trend < 0.05). Using the preferred linear model, we found 
significant increased risks of coronary heart disease (CHD) mortality and CVD mortality as well as 
combined fatal and non-fatal CHD, CVD, carotid atherosclerosis disease and hypertension in those 
exposed to drinking water with an As concentration of 10 µg/L compared to the referent (drinking 
water As concentration of 1 µg/L) population. Notwithstanding limitations included, the observed 
significant increased risks of CVD endpoints arising from As concentrations in drinking water 
between 1 µg/L and the 10 µg/L suggests further lowering of this guideline value should be 
considered. 
Keywords: arsenic; low level; cardiovascular disease; dose-response; systematic review; meta-
analysis 
 
1. Introduction 
Originating from either geological or anthropogenic activities, arsenic (As) has been widely 
recognized since the 1950s as one of the most serious human carcinogens [1,2]. Ubiquitously present 
in the environment [3–5], exposure to As can take place via ingestion (oral), dermal contact, 
inhalation, and even parenteral routes [6], and can lead to a wide range of carcinogenic and non-
carcinogenic end-points [7,8]. Long-term As exposure is known to result in lung, bladder, liver, skin 
and kidney cancers [9]. Concerning non-carcinogenic endpoints, while skin lesions are considered to 
be a primary marker of As toxicity [10], it has also been reported to be associated with different 
neurological problems [11], increased risk of immune problems in new-born [12], infant infections 
[13], some reproductive health problems in pregnant women [14] and, importantly, cardiovascular 
diseases (CVD). A prospective study conducted in Bangladesh found an increased risk of mortality 
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from ischemic heart disease and cerebrovascular disease in populations exposed to high 
concentration of inorganic arsenic (iAs) in well water [15]. Similarly, in other studies, increased risk 
of hypertension [16], stroke [17] and changes in CVD biomarker levels [6,18] were observed 
associated with As exposure. Among all the adverse health risks from As exposure, CVD is regarded 
as the most serious non- carcinogenic detrimental health outcome [15,19]. 
The relationship between CVD and As exposure at As concentrations in drinking water greater 
than 100 µg/L is well established [17,18,20,21]. However, partly as a result of the joint effort by 
Environmental Protection Agency and National Academy of Sciences to define an As risk threshold, 
the need to determine the dose-response at lower concentrations is also well recognized [22]. 
Unfortunately, evidence for low concentration effects, especially below the WHO permissible limit 
(10 µg/L) has been controversial and inconsistent [23,24]. For example, a cross-sectional study 
conducted by Kunrath et al. [25] found an association between CVD risks and low-level As exposure, 
while other studies such as that of Jones, et al. [26] for hypertension and that of Monrad et al. [27] for 
myocardial infarction did not find similar associations. Such inconsistency might be related to 
limitations with sample size, exposure and outcome assessment as well as insufficient information 
on different CVD risk factors [26,28,29]. As the available scientific data do not allow characterization 
of a clear threshold below which CVD risk would be negligible [23,29] and the disagreements 
between individual studies are a clear problem for regulators who currently face mounting pressure 
to determine “better” regulatory limits for As in drinking water, the National Research Council has 
recommended the use of meta-analysis to quantify the dose-response relationship of different CVD 
endpoints to low-level As exposure [30]. Compared to individual studies where detecting the 
possible true effects is often prevented due to their relatively small number of participants, meta-
analysis could lower the background noise, reduce error and bias and is a rigorous, transparent and 
systematic approach in evaluating aggregated evidence to answer a specific question [31,32]. 
Existing meta-analyses and systematic reviews that include the lower end of the As exposure 
range have not clearly and quantitatively specified any increased risk below 10 µg/L of water As 
concentration possibly because of a lack of epidemiological data. These reviews notably include a) a 
qualitative systematic review of the epidemiologic evidences on the association of CVD and low, 
moderate and high As exposure [33], b) a meta-regression of the association between risk of CVD and 
As exposure at concentrations lower than those recommended by previous studies [34], c) shaping 
the dose-response effects on incidence of CVD endpoints of chronic exposure to low-moderate (< 100 
µg/L) and high levels (≥ 100 µg/L) of As [24], d) unveiling the epidemiologic evidence on the 
relationship between CVD and As exposure in studies that include the lower end of the exposure 
range [22], and e) qualitatively identifying an association between the prevalence of hypertension 
and both low and moderate-to-high As exposure [35]. 
Due to the recent publication of a number of key epidemiological studies [36] building upon our 
recent research in exposure science [37–39], we aimed to use meta-analysis to determine 
quantitatively the magnitude of increased CVD risks for the general population exposed at As 
concentrations lower than the WHO provisional guideline value for drinking water of 10 µg/L. We 
have also included some CVD biomarkers in the evaluation. 
2. Materials and Methods 
2.1. Data Sources 
We searched ISI Web of Science for studies published before December 2019 on the association 
between CVD risks including overall CVD, coronary heart disease (CHD), stroke, carotid 
atherosclerosis disease, hypertension and associated clinic markers and As exposure and for the 
general population. The medical subject headings (MeSH) used were "arteriosclerosis", 
"atherosclerosis", "carotid artery diseases", "cardiovascular diseases", "cerebrovascular disease", 
"cerebrovascular disorders", "coronary artery disease", "heart diseases", "hypertension", "infarct", 
"ischemia", "ischemic heart disease", "myocardial infarction", "peripheral vascular diseases", 
Int. J. Environ. Res. Public Health 2020, 17, 2536 3 of 24 
 
"peripheral arterial disease", "stroke" and were combined with "arsenic", "arsenic poisoning", 
"arsenicals", "arsenite" and "arsenate". The terms were combined with the Boolean operators "OR" or 
"AND". The reference lists and cross-references of eligible studies were also searched as were the 
bibliographies of recent systematic reviews and meta-analyses reported by Navas-Acien et al. [33], 
Phung et al. [34], Moon et al. [24], Tsuji et al. [22], Abhyankar et al. [35] and Chowdhury et al. [40]. 
Studies not published in English, related to specific scenario like childhood exposure or 
exposure during pregnancy or occupational exposure, or based on a specific form of As like arsenic 
trioxide (which is not the common form of As exposure in the general population) were excluded. 
The review of literature was conducted in accordance with the techniques specified by Stroup et al. 
[41] for meta-analysis of observational studies in epidemiology (MOOSE) and reporting was done 
based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria 
[32]. 
Based on the abstract review, studies were firstly excluded if (a) they were case reports or case 
series; (b) no original data were presented; (c) had no human records; or (d) the outcome measures 
were not related with mortality or morbidity risk of relevant CVD types and/or clinical indicators 
considered in this study. The full text of studies which was regarded as potentially eligible was then 
assessed and further excluded if they were (a) not related with dietary As exposure or not for the 
general population; (b) no available relative risk (risk ratios, odds ratios) and measures of variability 
of different types of CVD were mentioned; or c) no categorical As exposure (at least three categories) 
was used (Figure S1). The methodological quality of the studies was also assessed and those with 
missing data on, or incomplete definitions of, the study design, population, exposure condition, or 
outcome variables were excluded [42–49]. Furthermore, as it is difficult to convert plasma As to water 
As, we excluded two studies which could only provide plasma As concentration to lower the bias of 
exposure assessment [50,51]. In addition, as there was only one study analysing each of soluble E-
selectin, myeloperoxidase, plasminogen activator inhibitor-1 (PAI-1), soluble Intercellular Adhesion 
Molecule 1 (ICAM-1) and soluble Vascular cell adhesion protein 1 (VCAM-1) [18], carotid 
atherosclerosis indices (CAIs) [52], common carotid intima media thickness, plaque score and the 
presence of plaque in the common carotid [53], peripheral vascular disease [54,55] as well as some 
other CVD subtypes and clinic markers [21,27,56–61], respectively, these variables have not been 
included in our dose-response meta-analysis. Moreover, due to the fact that significant differences 
could be found regarding concentrations of matrix-metalloproteases (MMPs) using plasma vs. serum 
[62], we further excluded two studies which analysed the plasma MMPs and serum MMPs 
respectively to avoid bias in outcome ascertainment [18,21] (Figure S1). Two reviewers (LX and DM) 
independently reviewed the quality of the studies and differences were resolved by consensus and 
discussion. 
2.2. Data Extraction 
For each study that appeared to meet the inclusion criteria, we extracted data on the number of 
deaths or cases, person-years or total number of population, the measured risk values (e.g., rate ratio, 
hazard ratio, odds ratio) and their statistical uncertainty (95% confidence interval (CI)) for each As 
concentration category. In addition, we recorded the descriptive information including authors’ 
names, year of study publication, sampling method, sample size, study design, and outcome 
ascertainment as well as the adjustment for confounders. 
Similar to the method used by Moon et al. [24], we combined all measures of association (e.g., 
rate ratio, hazard ratio, odds ratio) in different studies for each CVD endpoint together, as the relative 
risk. For the exposure assessment, we abstracted the mean, median values, and the range of As 
concentration in each concentration category. Though drinking water was the main metric of As 
exposure, for studies where drinking water data was not directly available, we estimated the drinking 
water As concentration from either toenail As [19] using the following formulae (see equation (1) and 
(2)): 
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water As  µg/L  ≥ 1 (µg/L) = 10^(1.4 + 0.9×log
  
(toenail As, µg/kg)), (1)
water As  µg/L  < 1 (µg/L) = 10^(-0.4 + 0.9×log
10
(toenail As, µg/kg)), (2)
or from urinary As [63] using equation (3): 
water As  µg/L  = urinary As  µg/g creatinine ×mean urine creatinine (g/L), (3)
where it was assumed that each participant has a urine creatinine concentration equal to the overall 
mean in the Strong Heart Study baseline visit (1.3 g/L, Moon KA, unpublished data). The credibility 
about the estimation of drinking water As concentration from toenail As and urinary As is indicated 
by their successful use in previous meta-analysis studies such as those of Moon et al. [24]. 
2.3. Statistical Analysis 
A random-effects dose-response meta-analysis was conducted to estimate the pooled dose-
response relationship between the log-transformed relative risk of each CVD outcome and water As 
concentrations from the summarized data of multiple studies using the package ‘dosresmeta’ in R 
statistical software [64,65]. This ‘dosresmeta’ meta-analysis consists of a two-stage procedure, 
whereby the study-specific trends are firstly estimated and then pooled across studies. In this 
analysis, we assumed both a constant log-linear (log-transformed water As concentration) and a 
flexible non-linear (restricted cubic splines with knots at the 10th, 50th and 90th percentiles of log-
transformed water As concentration) associations. The median value was assigned as the 
concentration level for each concentration category and if the median value was not provided 
directly, the mean or the midpoint values were calculated instead [16,25,45,59,63,66–75]. For the 
calculation of the midpoint value for each concentration category, zero was used as the minimum if 
not available [16,25,66,68–73]. Furthermore, without available maxima values, the width of the 
highest concentration category was assumed to be equal to the next lowest category [16,25,66,68–73]. 
Pooled log-linear and non-linear relative risks for each CVD endpoint were estimated for water As 
concentration of 3 µg/L, 5 µg/L, 10 µg/L, 20 µg/L and 50 µg/L, using 1 µg/L of drinking water As as 
the reference exposure. 
Dose-response relationships for individual studies with at least three concentration categories 
were plotted using the ‘ggplot’ function in the ‘ggplot2’ package in R and the pooled dose-response 
relationship for each CVD endpoint was plotted using the ‘matplot’ function in R to visualize the 
predicted relative risks at higher As level compared with the referent concentration (1 µg/L). 
Forest plots were used to show the pooled relative risks (95% CI) for both individual studies and 
the overall one, comparing risk for chronic exposure to drinking water As of 10 µg/L with 1 µg/L 
using the ‘forestplot’ function of the ‘metafor’ package in R, with the sizes of the squares of individual 
study relative risks weighted by the inverse variance of the log-relative risk within each model. 
Specifically, both the individual and the overall pooled relative risks (95% CIs) in the forest plots 
were calculated via the dose-response meta-analysis through the ‘dosresmeta’ package in R. Model 
goodness-of-fit was assessed using deviance tests, coefficient of determination (R2 and adjusted R2) 
and Akaike’s information criterion (AIC) values via the ‘gof’ function in the ‘dosresmeta’ package in 
R. Furthermore, dose-response relationships for individual studies were overprinted by the pooled 
dose-response relationship for each CVD endpoint to visually test the model goodness-of-fit. 
Heterogeneity was assessed by P-heterogeneity (p < 0.05 being significant), I2-statistics (I2-statistic < 
25% indicating low heterogeneity, 25%–50% moderate, and > 50% high) and Cochran’s Q-statistic 
[76]. 
In addition, to examine the potential publication bias and small study effects, funnel plots for all 
the CVD endpoints and Egger’s test of funnel plot asymmetry for those with greater than two studies 
were created using the ‘metafor’ package in R. To be specific, the effect estimated from each study 
(log-relative risk) was plotted against the standard error of log-relative risk, with the funnel centred 
at the overall model estimate. 
Int. J. Environ. Res. Public Health 2020, 17, 2536 5 of 24 
 
Finally, sensitivity analyses were conducted. On one hand, to test the reliability and suitability 
of combining different exposure media, we conducted sensitivity analysis to estimate the 
relationships between CVD risks and drinking water As both linearly and non-linearly by excluding 
studies which did not provide water As concentrations directly. On the other hand, with the intention 
of analysing the effects of low-level As exposure, we also excluded studies with As concentration 
higher than 100 µg/L and conducted subgroup analysis only for low to moderate As concentrations 
(taken here to be < 100 µg/L), modelling its linear and non-linear associations with the CVD risks. 
All our data analysis was performed using R statistical software (R Foundation for Statistical 
Computing, Vienna, Austria), version 3.4.3 (R Foundation for Statistical Computing) and R Studio (R 
Studio Desktop 1.1.423) [65,77,78]. 
3. Results 
3.1. Study Characteristics 
For our systematic review and meta-analysis, we identified 28 studies which satisfied the 
inclusion criteria (Table S1). There were considerable variations across studies in terms of the study 
design, study areas, exposure assessment, methods of outcome ascertainment and adjustment for 
confounders. 
Among all these studies, there were 13 cohort studies [15,17,19,20,26,29,63,71,79–82], with one 
retrospective study [57], inferring causality between CVD endpoints and As exposure ; six cross-
sectional studies [59,66–68,70,75]; five case-control studies [16,69,72,73,83]; one ecological study [74]; 
and three case-cohort studies [20,36,84]. 
We have included studies from As-endemic areas, such as Bangladesh [15,17,20,67,70], China 
[66,68,79,83], Taiwan [69,71,72,81,82], Chile [16] and Mexico [59] where recorded As level in drinking 
water could be as high as 900 µg/L, and studies from what are generally considered as non-endemic 
areas such as parts of North America [19,63,84] and some European countries [29,74]. 
We observed substantial differences in the methods of exposure assessment across studies (Table 
S1): while most provided As concentrations directly in drinking water [17,20,67–69,72–74,79–82,84], 
some studies also reported exposure based on urine [26,29,36,63,66] or toenails [19]. In addition, 
although many studies analysed As exposure at the individual or household-level [59,73,80], some 
studies tested As exposure at the municipal- or village-level instead [74] and may have greater 
measurement error. Moreover, while several studies applied time-weighted average [17,29,70,80,84] 
or accumulative average [16,66,67,69–72], many studies still used As concentration analysed at one 
time point as a proxy for chronic exposure [15,20,68,73]. 
In this study, the different CVD outcomes considered were: carotid atherosclerosis [69,72,73], 
CHD [15,19,20,29,63,74,79,81,83,84], overall CVD [15,19,20,29,63,74,79,80,82], hypertension 
[16,26,59,66,67,70,71,75], stroke [15,17,19,20,29,36,57,63,74,79] and the CVD clinic markers considered 
were: QT prolongation [68,85] and pulse blood pressure [67,75]. There were considerable differences 
in the outcome ascertainment of these CVD endpoints with quality of those ascertainment methods 
varying across studies (Additional file 1: Table S1). On one hand, some researchers confirmed the 
outcomes through standard clinical practice or self-reporting information, for example, hypertension 
risk was identified via blood pressure tests by trained clinicians using a sphygmomanometer or self-
reporting information from either a physician’s diagnosis or the record of anti-hypertensive 
medication usage [16,26,66,70]. On the other hand, some outcomes were identified by reviewing 
relevant database or records, ranging from the US National Death Index [19], National Institute for 
Statistics [74] to National Death Registry in Taiwan [81,82] and some other hospitalization and death 
records [63]. 
Association between CVD risks and As exposure could vary by age, gender, smoking status, 
alcohol consumption, physical activity, diabetes and obesity status, education level as well as some 
other socio-economic factors, all of which might be either powerful predictors of CVD risks or 
important factors in As toxicity [86–94]. However, varied adjustment for these well-identified 
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potential confounders could be observed among different studies, leading to different magnitudes of 
associations estimated when combined in a meta-analysis. All the studies were adjusted for at least 
age and gender, while BMI [15,20,63,83,84], education level [15], and smoking status [19,20,63,81] 
were adjusted in some, and few studies had some other health and socio-economic indicators 
[29,63,74,81] adjusted for. Moon et al. [63], and Wade et al. [79] even adjusted for some more rarely 
used variables, notably estimated glomerular filtration rate, albuminuria and farm work. 
3.2. Pooled Association between As Level and CVD Risk 
Of the 28 selected studies, 22 studies included dose-response meta-analysis of mortality risk, of 
which there were seven for CHD, eight for CVD and seven for stroke. The 21 studies on combined 
fatal and non-fatal CVD risks included three studies on carotid atherosclerosis disease, four studies 
on CHD, two studies on CVD, eight studies on hypertension and four studies on stroke. Apart from 
those quantifying the risk of different CVD types, we also considered four studies for CVD clinic 
markers, including two studies for pulse blood pressure and two studies for QT prolongation (Table 
1). 
Table 1. Characteristics of studies included for dose-response meta-analysis. 
Study 
(year) 
Design Cases 
Person or 
person-years 
Exposure 
media 
Concentration 
category 
Median RR (95% CI) 
Mortality 
CHD 
Chen et al. 
[15] (2011) 
ir 
14 20,064 
water 
(µg/L) 
0.1–12.0 2.3 1 (referent) 
16 19,109 12.1–62.0 34.0 1.22 0.56 2.65 
15 18,699 62.1–148.0 101.0 1.49 0.70 3.19 
26 19,380 148.1–864.0 237.0 1.94 0.99 3.84 
D'Ippoliti 
et al. [29] 
(2015) 
ir 
684 771,860 
water 
(µg/L) 
< 10 7.4 1 (referent) 
573 713,276 10–20 12.9 1.40 1.19 1.64 
1014 904,129 > 20 29.7 1.46 1.07 2.01 
Medrano 
et al. [74] 
(2010) 
ci 
88,566 18,978,000 
water 
(µg/L) 
< 1 0.7 1 (referent) 
19,709 4,803,000 1–10 3.9 1.05 1.01 1.10 
4725 1,011,000 > 10 23.3 1.02 0.96 1.08 
Moon et 
al. [63] 
(2013) 
ir 
68 13,616 
urine (µg/g 
creatinine) 
< 5.8 4.2 1 (referent) 
67 13,430 5.8–9.7 7.5 0.99 0.70 1.41 
87 12,720 9.8–15.7 12.4 1.18 0.83 1.69 
119 12,033 > 15.7 21.8 1.71 1.19 2.44 
Chen et al. 
[81] (1996) 
ir 
4 2748 
water 
(µg/L) 
< 10 5 1 (referent) 
5 1417 10–500 255 3.30 0.80 13.69 
16 4309 ≥ 510 755 5.30 1.49 18.85 
Wade et 
al. [79] 
(2009) 
ir 
44 14,636 
water 
(µg/L) 
0–5 1.1 1 (referent) 
26 9047 5.1–20 11.8 1.07 0.64 1.78 
72 21,367 20.1–100 26.2 1.22 0.82 1.82 
17 3313 100.1–300 156.1 1.55 0.88 2.73 
2 249 Over 300 387.9 2.47 0.50 12.18 
Farzan et 
al.  [19] 
(2015) 
ir 
57 898 
toenail 
(µg/g) 
0.01–0.07 0.05 1 (referent) 
51 852 0.07–0.11 0.09 1.13 0.77 1.67 
46 754 0.11–3.26 0.23 1.22 0.82 1.82 
CVD 
Chen et al. 
[15] (2011) 
ir 
43 20,064 
water 
(µg/L) 
0.1–12.0 2.3 1 (referent) 
51 19,109 12.1–62.0 34.0 1.21 0.80 1.84 
41 18,699 62.1–148.0 101.0 1.24 0.80 1.93 
63 19,380 148.1–864.0 237.0 1.46 0.96 2.20 
Sohel et al. 
[80] (2009) 
ir 
147 114,068 
water 
(µg/L) 
< 10 0.7 1 (referent) 
168 139,233 10–49 31.8 1.03 0.82 1.29 
463 365,496 50–149 95.0 1.16 0.96 1.40 
318 241,930 150–299 201.2 1.23 1.01 1.51 
115 78,786 > 300 371.5 1.37 1.07 1.77 
D'Ippoliti 
et al. [29] 
(2015) 
ir 
2752 771,860 
water 
(µg/L) 
< 10 7.4 1 (referent) 
2115 713,276 10–20 12.9 1.28 1.08 1.51 
3514 904,129 > 20 29.7 1.36 1.06 1.74 
Medrano 
et al. [74] 
(2010) 
ci 
285,049 18,978,000 
water 
(µg/L) 
< 1 0.7 1 (referent) 
62,739 4,803,000 1–10 3.9 1.02 0.99 1.06 
13,962 1,011,000 > 10 23.3 1.03 0.98 1.08 
Moon et 
al. [63] 
(2013) 
ir 
86 13,616 
urine (µg/g 
creatinine) 
< 5.8 4.2 1 (referent) 
95 13,430 5.8–9.7 7.5 1.12 0.83 1.52 
115 12,720 9.8–15.7 12.4 1.26 0.92 1.73 
143 12,033 > 15.7 21.8 1.65 1.20 2.27 
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Wade et 
al. [79] 
(2009) 
ir 
97 14,636 
water 
(µg/L) 
0–5 1.1 1 (referent) 
42 9047 5.1–20 11.8 0.72 0.32 1.60 
113 21,367 20.1–100 26.2 0.79 0.34 1.86 
24 3313 100.1–300 156.1 0.62 0.10 3.70 
3 249 Over 300 387.9 1.70 0.51 5.72 
Farzan et 
al. [19] 
(2015) 
ir 
125 1987 
toenail 
(µg/g) 
0.01–0.07 0.05 1 (referent) 
103 1691 0.07–0.11 0.09 1.04 0.80 1.35 
84 1334 0.11–3.26 0.23 0.99 0.74 1.32 
Wang, et 
al. [82] 
(2005) 
ir 
428 19,360 
water 
(µg/L) 
<10 5.0 1 (referent) 
84 2130 10–49 29.5 0.95 0.74 1.21 
116 2317 50–499 274.5 1.34 1.08 1.66 
60 1165 ≥500 724.5 1.80 1.36 2.38 
Stroke 
D'Ippoliti 
et al. [29] 
(2015) 
ir 
660 771,860 
water 
(µg/L) 
< 10 7.4 1 (referent) 
448 713,276 10–20 12.9 1.33 1.12 1.58 
789 904,129 > 20 29.7 1.44 1.16 1.78 
Farzan et 
al. [19] 
(2015) 
ir 
15 233 
toenail 
(µg/g) 
0.01–0.07 0.05 1 (referent) 
16 243 0.07–0.11 0.09 1.28 0.64 2.61 
12 161 0.11–3.26 0.23 1.10 0.50 2.40 
Rahman et 
al. [17] 
(2014) 
ir 
62 38,198 
water 
(µg/L) 
< 10 1.7 1 (referent) 
196 156,362 10–49 21.1 1.20 0.92 1.57 
271 42,579 > 50 102.2 1.35 1.04 1.75 
Moon et 
al. [63] 
(2013) 
ir 
6 13,616 
urine (µg/g 
creatinine) 
< 5.8 4.2 1 (referent) 
17 13,430 5.8–9.7 7.5 1.41 0.54 3.67 
13 12,720 9.8–15.7 12.4 2.16 0.77 6.09 
18 12,033 > 15.7 21.8 3.03 1.08 8.50 
Chen et al. 
[15] (2011) 
ir 
43 20,064 
water 
(µg/L) 
0.1–12.0 2.3 1 (referent) 
51 19,109 12.1–62.0 34.0 1.35 0.75 2.43 
41 18,699 62.1–148.0 101.0 1.20 0.63 2.27 
63 19,380 148.1–864.0 237.0 1.07 0.54 2.12 
Wade et 
al. [79] 
(2009) 
ir 
53 14,636 
water 
(µg/L) 
0–5 1.1 1 (referent) 
16 9047 5.1–20 11.8 0.47 0.27 0.84 
41 21,367 20.1–100 26.2 0.51 0.34 0.79 
7 3313 100.1–300 156.1 0.25 1.10 2.95 
1 249 Over 300 387.9 1.02 0.16 6.71 
Medrano 
et al. [74] 
(2010) 
ci 
81,368 18,978,000 
water 
(µg/L) 
< 1 0.7 1 (referent) 
18,327 4,803,000 1–10 3.9 1.00 0.99 1.05 
3895 1,011,000 > 10 23.3 1.02 0.95 1.09 
Fatal and non-fatal 
Carotid atherosclerosis disease 
Wu et al. 
[69] (2006) 
cc 
25 64 
water 
(µg/L) 
≤ 50.00 25 1 (referent) 
46 95 50.01–100.00 75 1.90 0.90 3.80 
89 183 ≥ 100.01 125 2.60 1.30 5.00 
Hsieh et 
al. [72] 
(2008) 
cc 
17 48 
water 
(µg/L) 
< 10 5 1 (referent) 
23 61 10.1–50 30 1.80 1.00 3.20 
195 370 > 50 70 1.90 1.10 3.10 
Hsieh et 
al. [73] 
(2011) 
cc 
24 55 
water 
(µg/L) 
< 10 5 1 (referent) 
31 81 10.1–50.0 30 1.53 0.67 3.50 
325 720 > 50.0 70 2.01 1.05 3.85 
CHD 
Wade et 
al. [83] 
(2015) 
cc 
168 305 
water 
(µg/L) 
< 10 1.9 1 (referent) 
105 236 10–39 16.0 1.23 0.78 1.93 
11 26 > 40 58.6 4.05 1.10 14.99 
Moon et 
al. [63] 
(2013) 
ir 
202 12,146 
urine (µg/g 
creatinine) 
< 5.8 4.2 1 (referent) 
206 11,701 5.8–9.7 7.5 1.05 0.86 1.28 
197 11,305 9.8–15.7 12.4 0.95 0.77 1.19 
241 10,586 > 15.7 21.8 1.30 1.04 1.62 
James et 
al. [84] 
(2015) 
ir 
58 4806 
water 
(µg/L) 
1–20 5.7 1 (referent) 
18 1335 20–30 25.3 1.25 0.70 2.31 
16 534 30–45 35.1 2.14 1.22 3.98 
4 98 45–88 50.5 3.12 1.12 9.02 
Chen et al. 
[20] (2013) 
ir 
61 2823 
water 
(µg/L) 
0.1–25 5.1 1 (referent) 
72 2718 25.1–107 57.0 1.18 0.75 1.84 
75 2770 108–864 198.5 1.54 1.02 2.31 
CVD 
Moon et 
al. [63] 
(2013) 
ir 
265 12,146 
urine (µg/g 
creatinine) 
< 5.8 4.2 1 (referent) 
297 11,701 5.8–9.7 7.5 1.14 0.95 1.35 
291 11,305 9.8–15.7 12.4 1.05 0.87 1.26 
331 10,586 > 15.7 21.8 1.32 1.05 1.28 
Chen et al. 
[20] (2013) 
ir 
114 2823 
water 
(µg/L) 
0.1–25 5.1 1 (referent) 
120 2718 25.1–107 57.0 1.00 0.67 1.50 
132 2770 108–864 198.5 1.49 1.06 2.11 
Hypertension 
ir 93 618 < 538 269 1 (referent) 
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Wang et 
al. [71] 
(2011) 
103 721 
water 
(µg/L) 
538–700 619 1.18 0.60 2.34 
83 634 > 700 781 0.83 0.40 1.68 
Jones et al. 
[26] (2011) 
ir 
418 952 
urine 
(µg/L) 
< 4.2 2.1 1 (referent) 
451 1057 4.2 to 8.3 6.3 1.08 0.83 1.40 
446 1090 > 8.3 to 17.1 12.7 1.30 0.94 1.80 
446 1068 > 17.1 21.5 1.17 0.75 1.83 
Chen et al. 
[75] (2007) 
cc 
289 2242 
water 
(µg/L) 
0.1–8.0 2.8 1 (referent) 
274 2116 8.1–40.8 23.2 1.10 0.90 1.33 
273 2187 40.9–91.0 63.9 1.03 0.85 1.25 
259 2181 91.1–176.0 128.1 1.01 0.83 1.22 
265 2184 176.1–864.0 283.1 1.02 0.84 1.23 
Islam et al. 
[67] (2012) 
cc 
22 291 
water 
(µg/L) 
10–22 15.5 1 (referent) 
19 208 23–32 27.5 1.33 0.67 2.62 
13 252 33–261 180.0 1.10 0.49 2.44 
12 243 ≥ 262 376.0 0.96 0.42 2.23 
Li et al. 
[66] (2013) 
cc 
29 120 
water 
(µg/L) 
< 100 61.0 1 (referent) 
30 119 100 to 350 223.8 1.20 0.63 2.29 
45 121 > 350 427.7 1.87 1.02 3.42 
Mendez et 
al. [59] 
(2016) 
cc 
106 260 
water 
(µg/L) 
< 25.5 12.8 1 (referent) 
106 260 25.5–47.9 36.7 1.30 0.84 2.00 
109 259 47.9–79.0 63.5 1.27 0.82 1.94 
118 259 ≥ 79.0 94.6 1.41 0.91 2.17 
Hall et al. 
[16] (2017) 
cc 
140 323 
water 
(µg/L) 
< 60 30.0 1 (referent) 
246 482 60–859 459.5 1.33 0.98 1.79 
225 450 > 859 1258.5 1.42 1.04 1.92 
Rahman et 
al. [70] 
(1999) 
cc 
9 114 
water 
(µg/L) 
< 0 2 1 (referent) 
50 623 0–500 250 1.20 0.60 2.30 
93 576 500–1000 750 2.20 1.10 4.30 
55 282 > 1000 1250 2.50 1.20 4.90 
Stroke 
Tsinovoi et 
al. [36] 
(2018) 
ir 
150 637 
water 
(µg/L) 
2.72–3.72 3.3 1 (referent) 
138 622 4.75–5.88 5.3 0.97 0.73 1.30 
139 624 8.26–9.18 8.1 1.03 0.77 1.38 
119 606 11.99–16.72 13.9 0.87 0.64 1.18 
125 608 26.11–54.81 34.1 1.01 0.74 1.36 
Moon et al. 
[63] (2013) 
ir 
55 12,146 
urine (µg/g 
creatinine) 
< 5.8 4.2 1 (referent) 
75 11,701 5.8–9.7 7.5 1.18 0.82 1.69 
62 11,305 9.8–15.7 12.4 1.16 0.77 1.72 
72 10,586 > 15.7 21.8 1.47 0.97 2.21 
Chen et al. 
[20] (2013) 
ir 
50 2823 
water 
(µg/L) 
0.1–25 5.1 1 (referent) 
46 2718 25.1–107 57.0 0.86 0.49 1.51 
52 2770 108–864 198.5 1.38 0.84 2.27 
Ersboll et 
al. [57] 
(2018) 
ir 
486 172,202 
water 
(µg/L) 
0.049–0.573 0.435 1 (referent) 
657 180,891 0.573–0.760 0.584 1.21 1.07 1.36 
475 169,470 0.760–1.933 1.174 1.05 0.92 1.19 
577 173,856 1.933–25.34 2.109 1.17 1.04 1.32 
CVD markers 
Pulse blood pressure (SBP-DBP ≥ 55 mmHg)) 
Chen et al. 
[75] (2007) 
cc 
205 2242 
water 
(µg/L) 
0.1–8.0 2.8 1 (referent) 
252 2116 8.1–40.8 23.2 1.39 1.14 1.71 
232 2187 40.9–91.0 63.9 1.21 0.99 1.49 
227 2181 91.1–176.0 128.1 1.19 0.97 1.45 
233 2184 176.1–864.0 283.1 1.19 0.97 1.46 
Islam et al. 
[67] (2012) 
cc 
5 291 
water 
(µg/L) 
10–22 15.5 1 (referent) 
10 208 23–32 27.5 3.87 1.22 12.2 
10 252 33–261 180.0 4.32 1.23 15.11 
16 243 ≥ 262 376.0 7.32 2.18 24.60 
QT prolongation 
Chen et al. 
[85] (2013) 
ir 
57 371 
water 
(µg/L) 
0.1–9 2.8 1 (referent) 
63 369 9.5–57 30.0 1.10 0.74 1.63 
49 374 58–144 95.1 0.87 0.57 1.31 
68 353 145–790 254.5 1.31 0.87 1.96 
Mumford 
et al. [68] 
(2007) 
cc 
4 103 
water 
(µg/L) 
< 21 10.7 1 (referent) 
12 108 100–350 199.9 3.83 1.13 12.99 
21 102 430–690 568.3 8.85 2.72 28.75 
CVD: cardiovascular disease; CHD: coronary heart disease. RR: Relative risk or approximation of the 
relative risk (rate ratio, risk ratio, odds ratio). ir: Risks estimated in the studies as rate ratio (incidence-
rate data); ci: Risks estimated in the studies as risk ratio (cumulative incidence data); cc: Risks 
estimated in the studies as an odds ratio (see details reported by Orsini et al. [65]). 
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Individual dose-response information of all the studies included in our dose-response meta-
analysis is presented in Table 1 and Figure 1. In the linear model, there was a significant overall trend 
for the mortality risk of CHD and CVD with an increase in As concentration (p < 0.05) (Table 2, Figure 
2). Compared to 1 µg/L as the reference level, the relative mortality risk of CHD and CVD at 10 µg/L 
drinking water As concentration was 1.498 (95% CI: 1.153–1.948) and 1.174 (95% CI: 1.049–1.313), 
respectively (Table 2). Similarly, significantly overall trend (p < 0.05) was also obtained for the 
combined fatal and non-fatal risk of CHD, CVD, carotid atherosclerosis disease and hypertension 
with the relative risks of these four endpoints at 10 µg/L of water As concentration were 1.405 (95% 
CI: 1.183–1.667), 1.411 (95% CI: 1.242–1.603), 1.936 (95% CI: 1.403–2.671) and 1.231 (95% CI: 1.043–
1.452), respectively, compared with 1 µg/L as the reference (Table 2 and Figure 2). 
 
Figure 1. Individual study dose-response characteristics for various CVD subtypes or biomarkers. 
Arsenic concentrations refer to the observed or estimated median arsenic concentrations for the given 
concentration category. Lines connect the dose-response data for each study and are for illustrative 
purposes only (CVD: cardiovascular disease; CHD: coronary heart disease). 
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Table 2. Pooled relative risks (95% CIs) for different types of cardiovascular disease (CVD) and clinic markers in relation to water arsenic concentrations. 
 
Mortality Risk Combined Fatal and Non-Fatal Risk CVD Markers 
CHD (7(25))a 
CVD 
(8(31))a 
Stroke 
(7(25))a 
CHD 
(4(14))a 
CVD 
(2(7))a 
Stroke 
(4(16))a 
Carotid 
atherosclerosis 
disease (3(9))a 
Hypertensi
on (8(30))a 
Pulse blood 
pressure 
(2(9))a 
QT 
prolongation 
(2(7))a 
Log-linear dose-response association model 
1 µg/L b 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
3 µg/L 
1.213 
(1.070, 1.374) 
1.079 
(1.023, 
1.139) 
1.061 
(0.891, 1.262) 
1.176 
(1.083, 
1.276) 
1.178 
(1.108, 
1.252) 
1.051 
(0.992, 
1.114) 
1.370 
(1.175, 1.598) 
1.104 
(1.020, 
1.195) 
1.187 
(0.848, 1.662) 
1.363 
(0.770, 2.414) 
5 µg/L 
1.327 
(1.105, 1.593) 
1.118 
(1.034, 
1.210) 
1.090 
(0.844, 1.407) 
1.268 
(1.125, 
1.429) 
1.272 
(1.163, 
1.391) 
1.076 
(0.989, 
1.171) 
1.587 
(1.267, 1.987) 
1.156 
(1.030, 
1.298) 
1.286 
(0.785, 2.105) 
1.574 
(0.682, 3.636) 
10 µg/L 
1.498 
(1.153, 1.948) 
1.174 
(1.049, 
1.313) 
1.131 
(0.784, 1.630) 
1.405 
(1.183, 
1.667) 
1.411 
(1.242, 
1.603) 
1.111 
(0.984, 
1.254) 
1.936 
(1.403, 2.671) 
1.231 
(1.043, 
1.452) 
1.433 
(0.707, 2.901) 
1.914 
(0.578, 6.339) 
20 µg/L 
1.693 
(1.203, 2.380) 
1.232 
(1.064, 
1.426) 
1.173 
(0.729, 1.889) 
1.556 
(1.245, 
1.944) 
1.566 
(1.325, 
1.848) 
1.146 
(0.979, 
1.342) 
2.362 
(1.553, 3.590) 
1.310 
(1.057, 
1.625) 
1.597 
(0.637, 3.998) 
2.327 
(0.490,11.052) 
50 µg/L 
1.988 
(1.274, 3.103) 
1.313 
(1.085, 
1.589) 
1.233 
(0.662, 2.295) 
1.781 
(1.331, 
2.383) 
1.796 
(1.445, 
2.230) 
1.195 
(0.973 
1.469) 
3.071 
(1.777, 5.308) 
1.423 
(1.074, 
1.885) 
1.842 
(0.555, 6.109) 
3.012 
(0.394, 23.045) 
coefficient 0.1757 0.070 0.054 0.148 0.150 0.046 0.287 0.090 0.156 0.282 
p-value for trend c 0.003 0.005 0.510 < 0.001 < 0.001 0.090 < 0.001 0.014 0.320 0.290 
I2 d 79.7% 77.9% 89.0% 6.6% 17.4% 0.0% 17.5% 62.3% 80.4% 91.5% 
Cochran’s Q-
statistic 
29.54 31.70 54.78 3.21 1.21 2.88 2.43 18.56 5.10 11.7 
P-heterogeneity e < 0.001 < 0.001 < 0.001 0.360 0.271 0.409 0.297 0.097 0.024 0.006 
Non-linear dose-response association model (restricted cubic splines) 
1 µg/Lb 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
3 µg/L 
1.163 
(1.060, 1.276) 
0.999 
(0.983, 
1.014) 
1.092 
(0.862, 1.382) 
0.985 
(0.811, 
1.197) 
0.954 
(0.647, 
1.406) 
1.011 
(0.823, 
1.241) 
1.225 
(0.783, 1.917) 
1.012 
(0.944, 
1.085) 
1.578 
(0.707, 3.523) 
1.070 
(0.772, 1.483) 
5 µg/L 
1.250 
(1.090, 1.433) 
1.001 
1.136 
(0.807, 1.596) 
0.978 0.933 1.026 
1.347 
(0.699, 2.594) 
1.018 
1.951 
(0.601, 6.326) 
1.105 
(0.685, 1.781) 
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(0.980, 
1.023) 
(0.735, 
1.302) 
(0.528, 
1.648) 
(0.780, 
1.349) 
(0.920, 
1.128) 
10 µg/L 
1.387 
(1.135, 1.695) 
1.015 
(0.986, 
1.043) 
1.192 
(0.746, 1.902) 
0.986 
(0.663, 
1.468) 
0.915 
(0.410, 
2.040) 
1.063 
(0.766, 
1.474) 
1.537 
(0.612, 3.863) 
1.027 
(0.888, 
1.187) 
2.601 
(0.483, 
14.001) 
1.155 
(0.583, 2.288) 
20 µg/L 
1.557 
(1.182, 2.052) 
1.045 
(1.012, 
1.080) 
1.241 
(0.701, 2.195) 
1.124 
(0.720, 
1.754) 
0.963 
(0.371, 
2.499) 
1.120 
(0.791, 
1.586) 
1.800 
(0.605, 5.353) 
1.041 
(0.868, 
1.249) 
3.449 
(0.389, 
30.605) 
1.229 
(0.504, 2.996) 
50 µg/L 
1.846 
(1.231, 2.769) 
1.125 
(1.077, 
1.176) 
1.295 
(0.659, 2.542) 
1.795 
(1.029, 
3.131) 
1.199 
(0.439, 
3.273) 
1.214 
(0.834, 
1.769) 
2.394 
(0.852, 6.728) 
1.082 
(0.877, 
1.334) 
4.642 
(0.298, 
72.343) 
1.433 
(0.440, 4.667) 
p-value for trend f 0.006 < 0.001 0.750 0.047 0.078 0.340 < 0.001 0.200 0.150 0.270 
I2 d 69.8% 35.3% 80.0% 41.0% 53.7% 0.0% 0.0% 46.3% 73.1% 72.5% 
Cochran’s Q-
statistic 
39.75 21.65 60.02 10.16 4.32 5.59 2.58 26.07 7.43 7.27 
P-heterogeneity e < 0.001 0.086 < 0.001 0.117 0.115 0.470 0.629 0.025 0.024 0.026 
CVD: cardiovascular disease; CHD: coronary heart disease. a: Sum of studies included; the total number of relative risks in each model. b: treat 1 µg/L water arsenic 
concentration as the referent. c: p-value for linear trend from a Wald test of the coefficient for drinking water arsenic concentrations. d: Proportion of total variance due to 
between-study heterogeneity. e: p-value for heterogeneity is chi-square p-value of the Q-statistic. f: Non-linear trend p-value for the non-linear spline coefficient in a model 
with arsenic concentrations entered as a restricted cubic spline with knots at 10th, 50th and 90th percentiles of water arsenic concentration. 
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Figure 2. Pooled log-linear and non-linear relative risks and 95% confidence intervals (CIs) of different 
CVD endpoints in relation to the estimated drinking water arsenic concentration. Pooled log-linear 
and non-linear relative risks of CVD endpoints were estimated for drinking water arsenic 
concentrations with reference to an arsenic concentration of 1 µg/L. Solid lines (red) correspond to 
pooled relative risks of linear models with their 95% CIs represented as shaded regions (red). Pooled 
relative risks of non-linear models were represented by long-dash lines (blue) and their 95% CIs were 
plotted as shaded areas (blue). Log-linear models were estimated with log-transformed estimated 
drinking water arsenic concentration and non-linear associations were estimated from models with 
restricted cubic splines of log-transformed water arsenic concentration with knots at the 10th, 50th and 
90th percentiles of log-transformed water arsenic (CVD: cardiovascular disease; CHD: coronary heart 
disease). 
In the non-linear analysis, though the overall trend was significant (p < 0.05) for CHD and CVD 
mortality risks as well as the combined fatal and non-fatal risk of CHD and carotid atherosclerosis 
disease, significant increases in pooled relative risks at 10 µg/L drinking water As compared with 1 
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µg/L as a reference were only found for the mortality risk of CHD (relative risk: 1.387; 95% CI: 1.135–
1.695) (Table 2 and Figure 2). 
3.3. Heterogeneity 
Combined with the estimated I2 statistic, Cochran’s Q-statistic and p-values for heterogeneity as 
presented in Table 2 and the individual and pooled relative risks of different CVD endpoints at 10 
µg/L drinking water As in comparison with 1 µg/L shown in Figure 3, we found evidence of 
significantly high heterogeneity among the studies combined for the linear and non-linear analysis 
of the mortality risk of CHD, stroke and two CVD clinic markers (pulse blood pressure and QT 
prolongation) as well as the linear analysis of CVD mortality risk (heterogeneity p-values < 0.05 and 
I2 > 50%). 
 
Figure 3. Forest plot of individual study and pooled log-linear relative risks (95% confidence intervals 
(CIs)) of different CVD endpoints, comparing 10 µg/L with 1 µg/L drinking water arsenic 
concentration. The sizes of squares of the individual study relative risks were weighted by the inverse 
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variance of the log-relative risk within each model (CVD: cardiovascular disease; CHD: coronary 
heart disease). 
3.4. Model Goodness Assessment 
Deviance, p-value, R2, adjusted R2 and AIC, as well as the difference between dose-response 
relationships for individual studies and the pooled dose-response relationship for each CVD 
endpoint, have been used for the goodness-of-fit assessment (Table 3 and Figure S2). According to 
the results, except for the linear analysis of pulse blood pressure (p-values lower than 0.05), deviance 
tests indicated no overall lack of fit for other CVD endpoints. In addition, there was only a slight 
increase in the R2 and the adjusted R2 for non-linear models compared with linear ones for most CVD 
endpoints, indicating that non-linear models explained more the variation of CVD risks. Linear 
models are considered a better fit for all the CVD endpoints due to their lower AIC values. 
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Table 3. Goodness-of-fit assessment. 
Studies 
Mortality risk Combined fatal and non-fatal risk CVD markers 
CHD CVD Stroke CHD CVD Stroke 
Carotid atherosclerosis 
disease 
Hypertensio
n 
Pulse blood 
pressure 
QT 
prolongation 
Log-linear dose-response association model 
Deviance a 19.40 22.58 15.98 13.04 7.06 18.54 2.99 20.27 14.02 4.97 
Degrees of freedom b 17 22 17 9 4 11 5 21 6 4 
p-value c 0.306 0.426 0.526 0.161 0.133 0.070 0.702 0.504 0.029 0.291 
R2 0.320 0.258 0.027 0.537 0.798 0.134 0.844 0.230 0.066 0.185 
Adjusted R2 0.280 0.225 −0.031 0.486 0.748 0.055 0.813 0.193 −0.089 −0.019 
AIC 0.17 −6.77 6.58 −0.56 1.26 −2.22 3.38 −4.36 4.55 5.58 
Non-linear dose-response association model (restricted cubic splines) 
Deviance a 17.28 22.81 15.39 5.83 3.94 17.48 1.71 12.94 9.16 3.44 
Degrees of freedom b 16 21 16 8 3 10 4 20 5 3 
p-value c 0.367 0.354 0.496 0.666 0.267 0.064 0.789 0.880 0.103 0.328 
R2 0.373 0.620 0.035 0.512 0.564 0.110 0.892 0.199 0.292 0.435 
Adjusted R2 0.297 0.584 −0.085 0.390 0.273 −0.068 0.838 0.118 0.008 0.058 
AIC 29.95 5.89 23.86 12.34 10.37 16.45 13.75 23.55 12.16 11.43 
CVD: cardiovascular disease; CHD: coronary heart disease. a: Measure of the total absolute deviation between reported and predicted log-relative risk taking into account 
the covariance structure of the residuals. b: Degrees of freedom from the deviance statistic. c: p-value from test for model specification. AIC: Akaike’s information criterion. 
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3.5. Small-Study Effects Evaluation 
Funnel plots and Egger’s test of funnel plots asymmetry suggested potential bias for the 
mortality risk of CHD and CVD with their p-values for Egger’s Regression Test lower than 0.05 (Table 
S2 and Figure S3). 
3.6. Sensitivity Analysis 
Excluding studies which cannot provide drinking water As concentrations directly resulted in 
similar conclusions to the main test, with the relative risks for both pooled linear and non-linear 
models becoming lower but with heterogeneity remaining high (Table S3). 
Excluding studies with drinking water As concentration > 100 µg/L, the estimated pooled 
relative risks were higher for both pooled linear and non-linear models but heterogeneity was not 
reduced (Table S4). 
4. Discussion 
To our knowledge, this is the first dose-response meta-analysis estimating CVD risks from low-
level As exposure from drinking water with As concentrations lower than the WHO provisional 
guideline value of 10 µg/L, to which a large population is exposed globally [95]. In this study, we 
found a significant increase of 49.8 % and 17.4% of CHD and CVD mortality risks, as well as 40.5%, 
41.1%, 93.6% and 23.1% increased risk for combined fatal and non-fatal CHD, CVD, carotid 
atherosclerosis disease and hypertension at a drinking water As concentration of 10 µg/L compared 
to 1 µg/L based on the linear model, which is preferred over the non-linear model. Considering the 
sizable population exposed to such low-level As concentrations [95] and the high morbidity and 
mortality of CVD worldwide [96], such a proportional increase in CVD risks due to low-level 
drinking water As may lead to hundreds of thousands of additional CVD cases or even premature 
deaths, causing a serious cardiovascular health issue for people and health services around the world. 
Already, strong evidence of the relationships between As exposure and different CVD endpoints 
has been identified in several systematic reviews and meta-analysis. However, most reviews were 
either related with a higher level of As exposure (> 50 µg/L) [22,28,33,40,97] or only provided 
descriptive evaluations [23,28]. To our knowledge, only Moon et al. [24] dose-response meta-analysis 
was available on this subject, where 11 individual studies were integrated to evaluate linear and non-
linear associations between CVD incident risks and low-moderate water As. Compared to Moon et 
al. [24], our present analysis included not only several CVD types, but also two CVD clinical markers 
(QT prolongation and pulse blood pressure), providing a more comprehensive view of the possible 
effects of low-level As exposure. In addition, Moon et al. [24] estimated CVD relative risk by 
comparing 20 µg/L with 10 µg/L water As concentration, while in our study, we determined the 
relative risk at 10 µg/L and below, using 1 µg/L as the referent, addressing the gap, at least partly, on 
the CVD risks from low-level As exposure especially for As concentrations lower than the WHO 
provisional guideline value, to which a large population is exposed worldwide [95]. 
To reduce model misspecification, we conducted both a constant linear and a smooth non-linear 
model (restricted cubic splines with knots at the 10th, 50th and 90th percentiles of log-transformed water 
As) via a two-stage 'dosresmeta' function. Somewhat consistent with previous meta-analysis 
researches [22,24], differences in the linear and non-linear model outcomes could be observed; 
notably there was no significant increased risk at 10 µg/L As for any of the outcomes except for CHD 
mortality risk in the non-linear model. Such a phenomenon might be related to the small number of 
studies and relatively few exposure categories in each study, which may be underpowered to 
establish precise dose-response relationships between CVD risks and low As exposure. It was 
particularly the case for the combined fatal and non-fatal risk of CVD and two CVD markers, where 
only two studies were found for each of these outcomes. 
Importantly, our study could provide guidelines for future modelling assessment in 
epidemiological studies. We found the linear model better using AIC as the selection criteria 
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depicting the associations of low-level As concentration and CVD outcomes. Such a conclusion has 
already been confirmed by several epidemiological and biological studies [36,53,61]. However, it has 
been illustrated that several mechanisms of As toxicity, ranging from the generation of oxidative 
stress, inhibition of DNA repair to modulation of signal transduction pathways and perturbation of 
DNA methylation patterns, are likely to give rise to nonlinear dose-response relationships, especially 
at low concentrations [98,99]. Besides, one recent study also revealed a steeper increase at lower As 
concentrations for fatal CVD [29]. Considering our limited sample size which may prevent discerning 
statistical evidence of a departure from a constant linear dose-response association and the 
significantly non-linear trends detected for some CVD endpoints (p-value for non-linear trend lower 
than 0.05); it is, therefore, important to bear in mind that the non-linear analysis of As effects should 
not be neglected, calling for future individual-level studies with sufficient data on low level As 
exposure and adverse health effects. 
Unfortunately, our study also has several limitations, the most important of which might be the 
unavoidable heterogeneity in our meta-analysis. We assumed that the above-mentioned substantial 
differences in underlying population characteristics, adjustment for confounding, methods for 
outcome ascertainment and exposure assessment might be responsible for such heterogeneity. It has 
been well-documented that assessing As exposure via a biomarker of internal dose is of great 
importance as it could provide an integrated measure of all sources of exposure, not only from 
drinking water, but also from diet, soil and air particles [100,101]. It is especially the case for areas 
with low to moderate drinking water As concentrations, where drinking water might not be the major 
exposure pathway [102,103]. Notwithstanding this, different biomarkers reflect different periods of 
As exposure. For example, as toenails normally grow about 0.75 mm per month [104], they could 
reflect a long-term exposure, even remaining constant for up to 6 years [105]. Similarly, As levels in 
hair could reflect exposure from the past several months [97]. In contrast, urine and blood are 
regarded as measuring recent As exposure for only several days or hours, respectively, being 
recommended as a more reliable method for examining short-term exposure patterns [6,106]. Besides, 
the relationships between As concentrations in internal biomarker (urine, toenail, hair or plasma) and 
drinking water still are not well understood, based not only on the magnitude, frequency and 
duration of environmental As exposure, but also on the individual variability associated to 
metabolism, body weight, urine dilution and toenail or hair characteristics [107–109]. Therefore, the 
pooled estimation with As concentrations from different exposure media in the present study may 
result in exposure misclassification, particularly at our low drinking water As concentrations at 
which both diet and water can contribute substantially to total As exposure. Nevertheless, some 
assumptions are necessary to pool studies with different exposure metrics and our sensitivity analysis 
excluding studies limited to biomarkers yielded similar conclusions. 
It is also important to understand that even though several perspective studies, such as the ones 
conducted by D'Ippoliti et al. [29] and Ersboll et al. [57] examined As exposure for a period of more 
than 20 years, the follow-up periods was still too short for the analysis of such low-level exposures 
(< 10 µg/L). Thus, more studies with longer periods of study period are warranted to confirm this 
association. Our meta-analysis might also be underpowered because of the small number of studies 
and concentration categories included in each CVD endpoint, producing a challenge for 
distinguishing the sources of heterogeneity. Furthermore, there was a lack-of-fit for the linear analysis 
of pulse blood pressure in this study, requiring further model improvement. Overall, given the high 
prevalence of low As exposure from different sources worldwide, long-term prospective studies with 
sufficient and high quality outcomes and exposure assessment at the individual level are needed [28]. 
These findings shed light, at least in part, on low-level As exposure induced health risks, 
suggesting that a consideration of downward revision of the WHO provisional guide value may be 
indicated to protect better human health and to reduce the economic burden arising from CVD 
related outcomes, even in countries such as the UK, where relatively few individuals consume 
drinking water with more than 10 µg/L As [39], but over 20 million people consume drinking water 
with between 1 µg/L As and 10 µg/L As [38]. Future carefully designed larger-scale perspective 
studies with sufficient individual data of CVD risk and low level environmental As exposure from 
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different sources are necessary to evaluate the association between As exposure and increases in CVD 
risk. 
5. Conclusions 
Our meta-analysis indicates an overall positive association between CVD risks and low level (1 
µg/L to 10 µg/L) As concentration in drinking water. For the general population, those with chronic 
exposure to As in drinking water at the WHO provisional guideline value limit (10 µg/L) compared 
to a reference population with 1 µg/L As are modelled to have significant excess CHD (50% (95% CI: 
15%–95%)) and CVD (17% (95% CI: 5%–31%)) mortality risks, as well as significant excess combined 
fata land non-fatal risks of CHD (41 % (95% CI: 18%–67%)), CVD (41% (95% CI: 24%–60%)), carotid 
atherosclerosis (94% (95% CI: 40%–167%)) and hypertension (23% (95% CI: 4%–45%)). Given the high 
mortality and morbidity of CVD risks in the world [96], such an increase in the relative risks related 
to low-level As exposure would give rise to a large absolute number of CVD patients and avoidable 
premature deaths, as well as a substantive increase in the financial burden on health service systems. 
Uncertainties and limitations of the available data and models indicate that further studies 
particularly those aiming to provide a deeper mechanistic understanding of the link between CVD 
and exposure to As are warranted, as well as a consideration of tightening the existing WHO 
provisional guideline value for arsenic in drinking water. 
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